ApoB/ApoA-I ratio in young patients with ischemic cerebral stroke or peripheral arterial disease

Translational Research

Volumn 152, Issue 3, 2008, Pages 113-118

  Sabino, Adriano Paula ^a   De Oliveira Sousa, Marinez ^a   Lima, Luciana Moreira ^a   Ribeiro, Daniel Dias ^a   Dusse, Luci Maria Sant'Ana ^a   Carvalho, Maria Das Graças ^a   Fernandes, Ana Paula ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTHROMBIN; SEX HORMONE; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DISEASE; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DISEASE MARKER; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; STENOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; FEMALE; HUMANS; LIPIDS; MALE; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; STROKE;

EID: 51749113981     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.06.005     Document Type: Article

References (36)

1. Keil U., Liese A.D., Hense H.W., et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Eur Heart J 19 (1998) 1197-1207
2. Lewington S., Clarke R., Qizilbash N., Peto R., and Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 360 (2002) 1903-1913
3. Bots M.L., Elwood P.C., Nikitin Y., et al. Total and HDL cholesterol and risk of stroke. Eurostroke: a collaborative study among research centres in Europe. J Epidemiol Community Health 56 suppl 1 (2002) i19-i24
4. Takaishi H., Taniguchi T., Fujioka Y., Ishikawa Y., and Yokoyama M. Impact of increasing diabetes on artery coronary disease in the past decade. J Atheroscler Thromb 11 (2004) 271-277
5. Jeffrey T., Lu A.B., Mark A., and Creager M.D. The relationship of cigarette smoking to peripheral arterial disease. Rev Cardiovasc Med 5 (2004) 189-193
6. Hankey G.J. Potential new risk factors for ischaemic stroke: what is their potential. Stroke 37 (2006) 2181-2188
7. Walldius G., Jungner I., Aastveit A., Holme I., and Sniderman A.D. Increased risk of fatal myocardial infarction related to high triglycerides, high apoB and low apoA-I in the AMORIS study. Diabetes 51 suppl (2002) A20
8. Walldius G., and Jungner I. Apolipoprotein B and apoliprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Internal Med 255 (2004) 188-205
9. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
10. Bathia M., Howard S.C., Clark T.G., et al. Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack. Cerebrovasc Dis 21 (2006) 323-328
11. Walldius G., Aastveit A.H., and Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 259 (2006) 259-266
12. Walldius G., and Jungner I. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol 22 (2007) 359-367
13. Sabino A.P., Ribeiro D.D., Carvalho M.G., Cardoso J., Dusse L.M.S., and Fernandes A.P. Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. Blood Coagul Fibrinolysis 17 (2006) 271-275
14. Friedewald W.T., Levy R.I., and Fredickison D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifugue. Clin Chem 18 (1972) 499-552
15. Sabino A, Fernandes AP, Lima LM, et al. Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease. J Thromb Thrombolysis. In press.
16. Schulz U.G., and Rothwell P.M. Differences in vascular risk factors between etiological subtypes of ischaemic stroke: importance of population-based studies. Stroke 34 (2003) 2050-2059
17. Ohira T., Shahar E., Chambless L.E., Rosamond W.D., Mosley Jr. T.H., and Folsom A.R. Risk factors for ischaemic stroke subtypes: the atherosclerosis risk in communities study. Stroke 37 (2006) 2493-2498
18. Petty G.W., Brown Jr. R.D., Whisnant J.P., Sicks J.D., O'Fallon W.M., and Wiebers D.O. Ischaemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 30 (1999) 2513-2516
19. Schneider A.T., Kissela B., Woo D., et al. Ischaemic stroke subtypes: a population-based study of incidence rates among blacks and whites. Stroke 35 (2004) 1552-1556
20. Falk R.H. PFO or UFO?. The role of a patent foramen ovale in cryptogenic stroke. Am Heart J 121 (1991) 1264-1266
21. Leung D.Y., Black I.W., Cranney G.B., et al. Selection of patients for transesophageal echocardiography after stroke and systemic embolic events. Role of transthoracic echocardiography. Stroke 10 (1995) 1820-1824
22. Powell J.T., Edwards R.J., Worrell P.C., Franks P.J., Greenhalgh R.M., and Poulter N.R. Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study. Atherosclerosis 129 (1997) 41-48
23. Stojakovic T., Scharnagl H., März W., Winkelmann B.R., Boehm B.O., and Schmut O. Low density lipoprotein triglycerides and lipoprotein(a) are risk factors for retinal vascular occlusion. Clin Chim Acta 382 (2007) 77-81
24. Walldius G., Jungner I., Aastveit A.H., Holme I., Furberg C.D., and Sniderman A.D. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 42 (2004) 1355-1363
25. Ritchie R.F., Palomaki G.E., Neveux L.M., et al. Reference distributions for apolipoproteins A-I and B and the apolipoprotein B/AI ratios: a practical and clinically relevant approach in a large cohort. J Clin Lab Anal 20 (2006) 209-217
26. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
27. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 suppl (2004) II-2-II-10
28. Devaraj S., Xu D.Y., and Jialal I. C-reactive protein increases plasminogen activator inhibitor 1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107 (2003) 398-404
29. Calabro P., Willerson J.T., and Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 (2003) 1930-1932
30. Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol. Atherosclerosis. In press.
31. Endres M. Statins and stroke. J Cereb Blood Flow Metab 25 (2005) 1093-1110
32. Endres M. Statins: potential new indications in inflammatory conditions. Atherosclerosis suppl 7 (2006) 31-35
33. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
34. Waters D.D., Schwartz G.G., Olsson A.G., et al. Reducing the risk for stroke in patients with myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 106 (2002) 1690-1695
35. Mora S., and Ridker P.M. Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER) -can C-reactive protein be used to target statin therapy in primary prevention?. Am J Cardiol 97 suppl (2006) 2A
36. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965